also found that the plasma levels of CCL1, CCL2, CXCL2, CXCL9, CXCL10, and CXCL11 are all remarkably reduced following anti-TB chemotherapy, suggesting that they can be added to host chemokine panels for treatment-response monitoring. This evidence concerns the gene CXCL10 and tuberculosis.